Ken Griffin Aslan Pharmaceuticals LTD Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.36 - $24.24 $12,016 - $809,106	33,379 Added 1.25%	2,698,518 $971,000
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.9 $12,874 - $32,186	-35,763 Reduced 1.32%	2,665,139 $1.33 Million
Q1 2022 May 16, 2022	SELL	$0.74 - $1.22 $12,583 - $20,746	-17,005 Reduced 0.63%	2,700,902 $2.39 Million
Q4 2021 Feb 14, 2022	SELL	$1.11 - $1.86 $34,534 - $57,868	-31,112 Reduced 1.13%	2,717,907 $3.04 Million
Q3 2021 Nov 15, 2021	SELL	$1.78 - $3.41 $265,716 - $509,041	-149,279 Reduced 5.15%	2,749,019 $4.89 Million
Q2 2021 Aug 16, 2021	BUY	$2.5 - $3.72 $5.61 Million - $8.35 Million	2,245,787 Added 344.18%	2,898,298 $9.56 Million
Q1 2021 May 17, 2021	BUY	$1.86 - $5.25 $1.15 Million - $3.24 Million	616,566 Added 1715.3%	652,511 $2.19 Million
Q4 2020 Feb 16, 2021	BUY	$1.54 - $2.22 $55,355 - $79,797	35,945 New	35,945 $66,000

Ticker ASLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,744,704
Market Cap $41.8M
Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-m...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.